MedTrace Logo

Trifecta-Kidney cfDNA-MMDx Study

NCT04239703 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2026-03-18

No results posted yet for this study

Summary

Demonstrate the relationship between DD-cfDNA levels and HLA antibodies in blood, and the Molecular Microscope® (MMDx) Diagnostic System results in indication biopsies.

Conditions

  • Kidney Transplant Rejection

Interventions

DIAGNOSTIC_TEST

MMDx

Portion of kidney transplant indication biopsy

DIAGNOSTIC_TEST

Prospera

Transplant patient blood sample

DIAGNOSTIC_TEST

HLA antibody

Transplant patient blood sample

Sponsors & Collaborators

  • Natera, Inc.

    collaborator INDUSTRY

  • One Lambda

    collaborator UNKNOWN

  • University of Alberta

    lead OTHER

Principal Investigators

  • Philip F Halloran, MD, PhD · University of Alberta

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-12-01
Primary Completion
2026-12-31
Completion
2027-12-31

Countries

  • United States
  • Australia
  • Canada
  • Croatia
  • Czechia
  • Germany
  • Lithuania
  • Poland
  • Slovenia
  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04239703 on ClinicalTrials.gov